1589082-06-3

Basic information

• Product Name: (S)-3-cyanomethylpiperazine-1-carboxylic acid tert-butyl ester
• Synonyms: (S)-3-cyanomethylpiperazine-1-carboxylic acid tert-butyl ester
• CAS NO: 1589082-06-3
• Molecular Weight: 225.291
• Mol File: 1589082-06-3.mol

Chemical Properties

• CAS DataBase Reference: (S)-3-cyanomethylpiperazine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-cyanomethylpiperazine-1-carboxylic acid tert-butyl ester(1589082-06-3)
• EPA Substance Registry System: (S)-3-cyanomethylpiperazine-1-carboxylic acid tert-butyl ester(1589082-06-3)

Safety Data

• Hazardous Substances Data: 1589082-06-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-cyanomethylpiperazine-1-carboxylic acid tert-butyl ester is used as a chemical compound for the development of new drugs. Its application is based on the fact that piperazine derivatives, to which it belongs, are known to exhibit a wide range of biological activities, making them promising candidates for medicinal purposes.
Used in Synthesis of Other Compounds:
(S)-3-cyanomethylpiperazine-1-carboxylic acid tert-butyl ester is used as a precursor in the synthesis of other compounds for medicinal purposes. Its application is due to its specific properties as an ester form of the (S)-3-cyanomethylpiperazine-1-carboxylic acid, which may be utilized to create additional compounds with potential pharmaceutical applications.

Upstream product

• 2306248-13-3 tert-butyl 3-(cyanomethyl)piperazine-1-carboxylate 
• 2158301-19-8 (±)-2-piperazin-2-ylacetonitrile dihydrochloride 
• 70403-11-1 2-(1,4-dibenzyl-2-piperazinyl)acetonitrile 
• 1450620-52-6 tert-butyl (3aR)-1,1-dioxotetrahydro-1H-1λ⁶-[1,2,3]oxathiazolo[3,4-a]pyrazine-5(3H)-carboxylate 
• 13435-20-6 tetraethylammoniumcyanide 
• 2158302-00-0 O¹-benzyl O⁴tert-butyl (2S)-2-(cyanomethyl)piperazine-1,4-dicarboxylate 
• 1450620-51-5 tert-butyl (3aR)-1-oxotetrahydro-1H-1λ⁴-[1,2,3]oxathiazolo[3,4-a]pyrazine-5(3H)-carboxylate 
• 278788-66-2 (R)-tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate 

Downstream Products

• 2158301-19-8 2-[(2S)-piperazin-2-yl]acetonitrile dihydrochloride 
• 2158302-00-0 O¹-benzyl O⁴tert-butyl (2S)-2-(cyanomethyl)piperazine-1,4-dicarboxylate 
• 2306255-32-1 (2S)-2-(cyanomethyl)piperazine-1-carboxylic acid benzyl ester 

Relevant articles and documents

SPIROCYCLIC TETRAHYDROQUINAZOLINES

Provided are compounds represented by Formula I, wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and (aa) are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula (I) are KRAS inhibitors and are thus useful to treat cancer and other diseases.

Spirocyclic tetrahydroquinazolines

The invention discloses spirocyclic tetrahydroquinazolines , and particularly provide compounds represented by Formula I shown in the specification, and pharmaceutically acceptable salts and solvates thereof. In the formula, R3, A, A1, A2, A3, E, E1, E2, L, Q, Z and a structure shown in the specification are as defined in the specification,. The compounds of formula I are KRAS inhibitors and are therefore useful in the treatment of cancer and other diseases.

Kras-G12C inhibitor heterocyclic compounds

The invention relates to Kras-G12C inhibitor heterocyclic compounds represented by formula I, a preparation method thereof, and application of the Kras-G12C inhibitor heterocyclic compounds in prevention and treatment of tumor diseases such as lung cancer, colorectal cancer and pancreatic cancer. In the preparation process, the compounds of the general formula I are obtained through a series of reactions such as SN2 reaction, protection, coupling reaction, deprotection, condensation reaction and the like.

COVALENT RAS INHIBITORS AND USES THEREOF

The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.

KRAS MUTANT PROTEIN INHIBITOR

Provided herein are a KRAS mutant protein inhibitor, as shown by formula (I), a composition containing the inhibitor and the use thereof.

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12CInhibitor for the Treatment of Cancer

Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target's resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRASG12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12. Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogues were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clinical development candidate MRTX849 as a potent, selective covalent inhibitor of KRASG12C is described.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRAS G12C INHIBITORS

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C

The present invention provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.